These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 8846618)

  • 21. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A; Belpaire FM
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetics and drug interactions of antidepressive agents].
    Sawada Y; Ohtani H
    Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.
    Ereshefsky L; Riesenman C; Lam YW
    J Clin Psychiatry; 1996; 57 Suppl 8():17-24; discussion 25. PubMed ID: 8698676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.
    Riesenman C
    Pharmacotherapy; 1995; 15(6 Pt 2):84S-99S. PubMed ID: 8587855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
    Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
    J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
    Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
    J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in interactions of SSRIs.
    Brøsen K
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
    Preskorn SH; Alderman J; Chung M; Harrison W; Messig M; Harris S
    J Clin Psychopharmacol; 1994 Apr; 14(2):90-8. PubMed ID: 8195463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E; Santoro V; D'Arrigo C
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some aspects of genetic polymorphism in the biotransformation of antidepressants.
    Brøsen K
    Therapie; 2004; 59(1):5-12. PubMed ID: 15199661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
    Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
    Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition by fluoxetine of cytochrome P450 2D6 activity.
    Otton SV; Wu D; Joffe RT; Cheung SW; Sellers EM
    Clin Pharmacol Ther; 1993 Apr; 53(4):401-9. PubMed ID: 8477556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
    Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
    Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P; Rochat B
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.